CHAN19107 / EA3161 / Megan Baumgart
Research Question:
Does maintenance immunotherapy (nivolumab) following definitive treatment with radiation
and chemotherapy (cisplatin) result in significant improvement in overall survival
(time being alive) and progression-free survival (time being alive without cancer)
for patients with intermediate risk human papillomavirus (HPV) positive oropharynx
cancer that has spread to nearby tissue or lymph nodes?
Basic Study Information
Purpose:
This phase III trials studies whether maintenance immunotherapy (nivolumab) following
definitive treatment with radiation and chemotherapy (cisplatin) result in significant
improvement in overall survival (time being alive) and progression-free survival (time
being alive without cancer) for patients with intermediate risk human papillomavirus
(HPV) positive oropharynx cancer (throat cancer) that has spread to nearby tissue
or lymph nodes. Drugs used in chemotherapy such as cisplatin work in different ways
to stop the growth of tumor cells, either by killing the cells, by stopping them from
dividing, or by stopping them from spreading. Radiation therapy uses high energy rays
to kill tumor cells and shrink tumors. Immunotherapy with monoclonal antibodies, such
as nivolumab, may help the body's immune system attack the cancer, and may interfere
with the ability of tumor cells to grow and spread. It is not yet known whether chemotherapy
and radiation therapy followed by maintenance nivolumab therapy works better than
chemotherapy and radiation therapy alone in treating patients with HPV positive oropharyngeal
cancer.
Location: University of Rochester Medical Center
Study Reference #: CHAN19107
Lead Researcher (Principal Investigator)
Lead Researcher:
Megan Baumgart
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search